Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events

This is a retrospective analysis of Fabry Outcome Survey data from children/adults (n = 677) receiving agalsidase alfa enzyme replacement therapy for a median of 3 years, examining cerebrovascular, cardiac, and renal morbidity endpoints separately. Cardiac events occurred at younger ages than cerebr...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michael Beck, Derralynn Hughes, Christoph Kampmann, Guillem Pintos-Morell, Uma Ramaswami, Michael L. West, Roberto Giugliani
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2018-03-01
Edice:	Molecular Genetics and Metabolism Reports
Témata:	Fabry disease Enzyme replacement therapy Agalsidase alfa Long-term effectiveness
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2214426917301039
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!